Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Shinji Mii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8266-3235; OpenAlex author ID A5066040234. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2022: 5 papers · 2023: none · 2024: none · 2025: none · 2026: 4 papers

Papers 9

  1. Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. Last author DOI 10.1007/s00795-025-00438-y↗
  2. Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1038/s41416-025-03299-5↗
  3. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  4. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  5. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Co-author DOI 10.1007/s00428-021-03230-2↗
  6. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  7. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  8. Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1111/pin.13198↗
  9. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… Co-author DOI 10.1245/s10434-022-12039-5↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Enomoto · 6 shared papers, 2022–2026 · strength 0.99
  2. Masamichi Hayashi · 4 shared papers, 2022–2026 · strength 0.70
  3. Mitsuro Kanda · 3 shared papers, 2022–2026 · strength 0.57
  4. Tomohisa Otsu · 2 shared papers, 2026 · strength 0.45
  5. Ryo Ashida · 2 shared papers, 2026 · strength 0.45
  6. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
  7. Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
  8. Junpei Yamaguchi · 2 shared papers, 2026 · strength 0.45
  9. Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
  10. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  11. Nobuhiko Nakagawa · 2 shared papers, 2026 · strength 0.45
  12. Yukihiro Yokoyama · 2 shared papers, 2026 · strength 0.45
  13. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  14. Keizo Fujita · 2 shared papers, 2026 · strength 0.45
  15. Tadashi Iida · 3 shared papers, 2022 · strength 0.37
  16. Yasuyuki Mizutani · 3 shared papers, 2022 · strength 0.37
  17. Takeshi Sudo · 1 shared paper, 2026 · strength 0.27
  18. Akira Ishikawa · 1 shared paper, 2026 · strength 0.27
  19. Shiro Oka · 1 shared paper, 2026 · strength 0.27
  20. Sho Tazuma · 1 shared paper, 2026 · strength 0.27
  21. Wataru Yasui · 1 shared paper, 2026 · strength 0.27
  22. Yasutaka Ishii · 1 shared paper, 2026 · strength 0.27
  23. Yuto Fujiki · 1 shared paper, 2026 · strength 0.27
  24. Reo Maruyama · 1 shared paper, 2026 · strength 0.25
  25. Keiko Shinjo · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.